Aniracetam

Modify Date: 2024-01-02 15:00:45

Aniracetam Structure
Aniracetam structure
Common Name Aniracetam
CAS Number 72432-10-1 Molecular Weight 219.236
Density 1.2±0.1 g/cm3 Boiling Point 399.7±34.0 °C at 760 mmHg
Molecular Formula C12H13NO3 Melting Point −58 °C(lit.)
MSDS Chinese Flash Point 195.5±25.7 °C

 Use of Aniracetam


Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.Target: AMPA; nAChRAniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam. It selectively modulates the AMPA receptor. It is lipid soluble and has possible cognition enhancing effects. It has been tested in animals extensively, Alzheimer's patients and temporarily-impaired healthy subjects. It has shown potential as an anxiolytic in three clinical animal models [1].Administration of aniracetam for 10 days (post-natal days (PND) 18-27), at a dose of 50 mg/kg reversed cognitive deficits in both rat genders, indicated by a significant increase in the number of avoidances and the number of 'good learners'. After the termination of the nootropic treatment, a significant increase in both amplitude and frequency of AMPA receptor-mediated mEPSCs in hippocampal CA-1 pyramidal cells was observed [2].Clinical indications: Cognitive disorder; StrokeFDA Approved Date: Toxicity: insomnia; headaches; nausea or rash.

 Names

Name aniracetam
Synonym More Synonyms

 Aniracetam Biological Activity

Description Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.Target: AMPA; nAChRAniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam. It selectively modulates the AMPA receptor. It is lipid soluble and has possible cognition enhancing effects. It has been tested in animals extensively, Alzheimer's patients and temporarily-impaired healthy subjects. It has shown potential as an anxiolytic in three clinical animal models [1].Administration of aniracetam for 10 days (post-natal days (PND) 18-27), at a dose of 50 mg/kg reversed cognitive deficits in both rat genders, indicated by a significant increase in the number of avoidances and the number of 'good learners'. After the termination of the nootropic treatment, a significant increase in both amplitude and frequency of AMPA receptor-mediated mEPSCs in hippocampal CA-1 pyramidal cells was observed [2].Clinical indications: Cognitive disorder; StrokeFDA Approved Date: Toxicity: insomnia; headaches; nausea or rash.
Related Catalog
References

[1]. Nakamura K, et al. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.

[2]. Vaglenova J, et al. Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors. Neuropsychopharmacology. 2008 Apr;33(5):1071-83. Epub 2007 Jul 4.

 Chemical & Physical Properties

Density 1.2±0.1 g/cm3
Boiling Point 399.7±34.0 °C at 760 mmHg
Melting Point −58 °C(lit.)
Molecular Formula C12H13NO3
Molecular Weight 219.236
Flash Point 195.5±25.7 °C
Exact Mass 219.089539
PSA 46.61000
LogP 0.27
Vapour density 4.9 (vs air)
Vapour Pressure 0.0±0.9 mmHg at 25°C
Index of Refraction 1.574
Storage condition Store at RT
Water Solubility Reacts

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UY5781900
CHEMICAL NAME :
2-Pyrrolidinone, 1-(4-methoxybenzoyl)-
CAS REGISTRY NUMBER :
72432-10-1
LAST UPDATED :
199806
DATA ITEMS CITED :
10
MOLECULAR FORMULA :
C12-H13-N-O3
MOLECULAR WEIGHT :
219.26

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 78,104,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1255 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 30,9,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,45,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>50 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 30,9,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3648 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Gastrointestinal - changes in structure or function of salivary glands
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 14(Suppl 4),673,1986
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1180 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - lacrimation Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 14(Suppl 4),673,1986
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,45,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 30,9,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 30,9,1994 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
26400 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 14(Suppl 4),691,1986

 Safety Information

Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS UY5781900

 Synthetic Route

~82%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: Karimi; Kihlberg; Langstroem Journal of the Chemical Society. Perkin Transactions 1, 2001 , # 13 p. 1528 - 1531

~%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: US4369139 A1, ;

~39%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: Zhang, Jian; Hong, Soon Hyeok Organic Letters, 2012 , vol. 14, # 17 p. 4646 - 4649

~%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: US4369139 A1, ;

~%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: US4369139 A1, ;

~70%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: Blay, Gonzalo; Cardona, Luz; Garcia, Begona; Garcia, Cristina L.; Pedro, Jose R. Tetrahedron Letters, 1997 , vol. 38, # 47 p. 8257 - 8260

~%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: US4369139 A1, ;

~%

Aniracetam Structure

Aniracetam

CAS#:72432-10-1

Literature: US4369139 A1, ;

 Articles32

More Articles
Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors.

J. Med. Chem. 53 , 2197-203, (2010)

Glutamate receptors are the most prevalent excitatory neurotransmitter receptors in the vertebrate central nervous system and are important potential drug targets for cognitive enhancement and the tre...

Glutamate Receptors within the Mesolimbic Dopamine System Mediate Alcohol Relapse Behavior.

J. Neurosci. 35 , 15523-38, (2015)

Glutamatergic input within the mesolimbic dopamine (DA) pathway plays a critical role in the development of addictive behavior. Although this is well established for some drugs of abuse, it is not kno...

Development and validation of a liquid chromatographic method for the simultaneous determination of aniracetam and its related substances in the bulk drug and a tablet formulation.

J. Pharm. Biomed. Anal. 56(3) , 615-22, (2011)

Simultaneous determination of aniracetam and its related impurities (2-pyrrolidinone, p-anisic acid, 4-p-anisamidobutyric acid and (p-anisoyl)-4-methyl-2-pyrrolidinone) was accomplished in the bulk dr...

 Synonyms

MFCD00153767
Ro 13-5057
Aniracetam
1-p-Anisoyl-2-pyrrolidinone
Sarpul
1-(4-Methoxybenzoyl)pyrrolidin-2-one
Ampamet
Draganon
1-[(4-Methoxyphenyl)carbonyl]pyrrolidin-2-on
2-Pyrrolidinone, 1-(4-methoxybenzoyl)-
1-anisoyl-2-pyrrolidinone
1-(4-Methoxybenzoyl)-2-pyrrolidinone
1-[(4-Methoxyphenyl)carbonyl]pyrrolidin-2-one
Top Suppliers:I want be here



Get all suppliers and price by the below link:

Aniracetam suppliers


Price: $95/10mM*1mLinDMSO

Reference only. check more Aniracetam price

Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3